证券日报网讯12月12日，海泰新光在互动平台回答投资者提问时表示，联营公司的整机产品2024年第二 季度才获批，下半年开始推广销售，目前销售数量还不多。今年联营公司加强内窥镜推广力度，产品得 到用户的初步认可。此外，由于当前产品较为单一，联营公司正在布局相关产品以扩展产品种类提高盈 利能力。 ...

Market Overview - The Shanghai Composite Index closed at 3889.35 points, with a change of 0.41% [1] - The total trading volume of A-shares reached 2119.01 billion yuan [1] Technical Analysis - 28 A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Hengfeng Information: -0.95% - Huaxia Happiness: -0.87% - Haitai New Light: -0.79% [1] Individual Stock Performance - Hengfeng Information (300605) saw a decline of 6.66% with a turnover rate of 18.06% [1] - Huaxia Happiness (600340) decreased by 1.63% with a turnover rate of 7.60% [1] - Haitai New Light (688677) increased by 1.19% with a turnover rate of 0.80% [1] - Jiangsu Beiren (688218) fell by 1.35% with a turnover rate of 3.68% [1] - Shenhui Technology (300853) decreased by 0.99% with a turnover rate of 2.24% [1] - Other notable declines include: - Zhongke Tongda (688038): -1.51% - Zhongke Information (300678): -0.37% - Fa Lion (605318): -0.91% [1] Additional Stock Movements - Stocks with minor declines include: - New Times (002527): -0.45% - Shanghai Environment (601200): -0.62% - Mind Electronics (300656): +0.29% [2] - The stock performance of various companies indicates a mixed market sentiment, with some stocks showing resilience while others face downward pressure [2]

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing a decline in stock price while benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise in the medical device sector [1][2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. The company specializes in the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition of the company includes 64.86% from medical endoscope devices, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%. The net profit attributable to the parent company was 136 million yuan, with a year-on-year increase of 40.03% [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company has a vertical integration capability in the medical device industry, being one of the few in China that can manage core components, key equipment, and system integration [2]. - It has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong innovation capabilities and market share [3]. Stock Market Activity - On December 11, the company's stock price fell by 2.49%, with a trading volume of 43.66 million yuan and a turnover rate of 0.82%, leading to a total market capitalization of 5.247 billion yuan [1]. - The stock has seen a net outflow of 12,500 yuan from major investors today, with a total net outflow of 503 million yuan from the industry over the past three days [4][5].

【海泰新光汪方华：光学技术为基 医疗赛道纵深拓展】在中美贸易环境持续演变的背景下，一批出口 导向型的中国制造企业正积极调整全球产能布局，以保持竞争力并开拓新机遇。 尽管光学技术在资本市场关注度较高，海泰新光仍坚持以利润为中心的经营策略。"医疗板块毛利率约 65%，净利率可达30%，回报稳定可观。光学很多领域虽在估值上受青睐，但对企业的实际利润支撑往 往不足。"汪方华坦言。 汪方华透露，未来，海泰新光投资将围绕光学与医疗两大方向：医疗领域以外科产品线为主，力求产品 组合完整、渠道扎实；光学领域更关注其长期技术价值与规模效应，即使短期利润贡献有限，也会持续 投入。此外，公司已在AI医疗领域有所布局，比如为医院检验科开发具备AI辅助判断功能的产品，并 推动相关注册工作。中经记者 陈婷 赵毅 北京报道 la � 1200 > F 6 @中国经营报 "真正的转折点在2023年。"汪方华表示，"我们看到整体国际环境并不乐观，于是在6月份启动泰国生产 基地建设，同时在美国设立小规模量产基地。"这一布局在2024年显示出其必要性——今年4月，美国对 部分中国产品加征关税最高达100%，若没有海外产能，产品将难以进入美国市场。 ...

中经记者 陈婷 赵毅 北京报道 12月10日，由中国经营报社主办的"大重构·大机遇——2025中国医药大健康产业论坛"在北京举行。会 上，海泰新光（688677.SH）董事会秘书汪方华详细阐述了公司如何通过前瞻性的国际化产能安排应对 关税挑战，并分享了以光学技术为核心、向医疗器械领域持续延伸的发展战略。 市场收入占比达60%—70%。汪方华预计，未来三到五年出口占比或将进一步上升。"随着新品推出， 单一客户占比可能从60%增至80%甚至更高。" 海泰新光目前主要聚焦于外科手术腹腔镜产品，并正沿光学产业链向下游延伸，布局医疗分析与检测类 产品。在泰国建厂不仅服务原有美国客户，也吸引了新客户借助该基地拓展美国市场，为公司带来增量 机遇。 尽管光学技术在资本市场关注度较高，海泰新光仍坚持以利润为中心的经营策略。"医疗板块毛利率约 65%，净利率可达30%，回报稳定可观。光学很多领域虽在估值上受青睐，但对企业的实际利润支撑往 往不足。"汪方华坦言。 在中美贸易环境持续演变的背景下，一批出口导向型的中国制造企业正积极调整全球产能布局，以保持 竞争力并开拓新机遇。 海泰新光主要从事医用内窥镜器械和光学产品的研发、生产和销 ...

新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李思阳 专题：2025中国企业竞争力年会 "2025中国企业竞争力年会"于12月9日至10日在北京举行，青岛海泰新光科技股份有限公司董事会秘书 汪方华在演讲中谈到，做医疗器械的产业链很长，他们核心技术是光学。 谈到在东南亚建厂，汪方华表示，早期可能人工也没有那么贵，土地也没有那么贵，但是随着中国的企 业很多往东南亚转，整个东南亚的人工、地皮就很贵。整体的经营环境，总体的感觉是没有熟悉的地方 好。 专题：2025中国企业竞争力年会 "2025中国企业竞争力年会"于12月9日至10日在北京举行，青岛海泰新光科技股份有限公司董事会秘书 汪方华在演讲中谈到，做医疗器械的产业链很长，他们核心技术是光学。 谈到在东南亚建厂，汪方华表示，早期可能人工也没有那么贵，土地也没有那么贵，但是随着中国的企 业很多往东南亚转，整个东南亚的人工、地皮就很贵。整体的经营环境，总体的感觉是没有熟悉的地方 好。 "我们在美国也有工厂，人不是很多，但是从中美泰来说，中国人的效率是最高的，所以不容易，但是 ...

Group 1 - The global macroeconomic environment has gradually improved since 2025, with corporate profit expectations and favorable policies driving the A-share market upward, with major indices like the CSI 300 and ChiNext Index showing cumulative gains exceeding 20% [3][42] - The technology, consumer, and new energy sectors have emerged as the main leaders in the market rally, with trading activity significantly increasing, as evidenced by a 15% year-on-year growth in average daily trading volume [3][42] - Equity funds have benefited from asset value growth and optimized investment strategies, with average returns for mixed equity funds surpassing 25% this year, and several thematic funds, such as those focused on artificial intelligence and high-end manufacturing, achieving gains over 40% [3][42] Group 2 - The Dachen Consumer Selected Stock A fund has underperformed, with a cumulative return of -18.82% since its inception, despite the overall bullish market conditions [3][22][61] - The fund's performance has been hindered by a heavy allocation to traditional consumer sectors like liquor and duty-free, which are facing demand ceilings, while emerging consumption areas such as instant retail and experience economy have not been adequately represented in the portfolio [8][47][56] - The fund's holdings in leading companies have seen a weakening of their competitive advantages, while new consumer brands have rapidly gained market share, indicating a need for the fund to reassess its thematic positioning and investment strategy [8][56][58] Group 3 - The Dachen Yuexiang Life Mixed A fund, established on December 10, 2021, has a current net asset value of 146 million yuan, with a unit net value of 0.8782 as of December 5, 2025, reflecting a significant underperformance compared to its peers [8][47][58] - The fund's net asset value has decreased by 5.12% in the latest reporting period, indicating ongoing challenges in attracting new investments, as evidenced by consistent redemptions across multiple quarters [57][58] - The fund's investment strategy has included significant positions in stocks like Kweichow Moutai and Luzhou Laojiao, which have seen substantial price declines during the holding periods, further contributing to the fund's poor performance [10][52][70]

Group 1: Manufacturing Industry Insights - The manufacturing sector in China is experiencing a significant upturn due to rising global electricity demand and the rapid adoption of AI technologies, with companies like Huaming Equipment benefiting from a 40% annual export growth over the past three years and a gross margin of 55.5% in its equipment business [6][2] - Huaming Equipment has a cost advantage of over 20% compared to its European and American counterparts, along with a delivery time that is 30%-50% shorter, positioning it well in the global market [6] - The re-industrialization trend globally is seen as a form of "Sinicization," where Chinese companies are well-equipped to meet industrial demands in regions lacking local manufacturing capabilities [8][6] Group 2: Real Estate and Manufacturing Relationship - The real estate sector has historically contributed to the development of manufacturing by providing infrastructure and financial support, although it has also created significant debt that needs to be addressed [3][2] - Local governments have utilized revenue from commercial land sales to improve the investment environment for manufacturing, indicating a symbiotic relationship between the two sectors [3] Group 3: Consumer Market Dynamics - Consumer demand in China is currently weak, with some sectors experiencing negative growth, such as the dairy industry, which saw a 2.8% decline in milk production last year [11] - The average value of goods in the express delivery sector has decreased by approximately 40% over the past five years, indicating heightened price sensitivity among consumers [12] - Despite limited growth in consumer spending, there remains potential for long-term growth in consumption, particularly in sectors where per capita consumption is still low compared to other countries [12][11] Group 4: Economic and Income Distribution Challenges - China's consumer spending rate is low, at around 37.2%, significantly below the average of 53.8% for 38 countries, indicating a need for improved income distribution and social security systems [17] - The low consumption tendency is attributed to factors such as high housing costs, a culture of saving, and inadequate social security, which collectively suppress consumer spending [20][17] - Addressing income inequality and enhancing the disposable income of lower-income groups are essential for boosting overall consumption in the economy [21][23]

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is focused on integrating optical technology with cutting-edge medical device applications, particularly in high-performance endoscope products, and has a strong vertical integration capability in the industry [2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. Its main business includes the research, development, production, and sales of medical endoscope devices and optical products [7]. - The revenue composition of the company is as follows: medical endoscope devices 64.86%, optical products 21.63%, maintenance services 13.09%, and leasing 0.42% [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 448 million yuan, representing a year-on-year growth of 40.47%. The net profit attributable to the parent company was 136 million yuan, with a year-on-year increase of 40.03% [7]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises that excel in niche markets and possess strong innovation capabilities [3]. - As of the latest report, 69.12% of the company's revenue comes from overseas markets, benefiting from the depreciation of the Chinese yuan [3]. Stock Performance - On December 4, the stock price of Haitai New Light decreased by 0.04%, with a trading volume of 27.27 million yuan and a turnover rate of 0.50%. The total market capitalization is 5.45 billion yuan [1]. - The average trading cost of the stock is 46.62 yuan, with recent buying activity observed, although the buying pressure is not strong. The stock is currently trading between a resistance level of 46.80 yuan and a support level of 42.48 yuan [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688677 证券简称：海泰新光 公告编号：2025-073 青岛海泰新光科技股份股份有限公司 关于控股股东、实际控制人 及其一致行动人权益变动 触及1%刻度的提示性公告 青岛海泰新光科技股份有限公司控股股东、实际控制人ZHENG ANMIN（郑安民）先生及其一致行动 人保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 2.信息披露义务人信息 特此公告。 ■ 3.一致行动人信息 ■ 二、权益变动触及1%刻度的基本情况 公司于2025年12月3日收到股东ZHENG ANMIN先生出具的《关于权益变动告知函》，ZHENG ANMIN 先生于2025年12月2日和12月3日通过大宗交易方式减持公司股份1,161,100股，占公司总股本的比例为 0.9686%。 本次权益变动后，公司实际控制人ZHENG ANMIN先生及其一致行动人合计持有公司股份数量由 44,290,000股减少至 ...